506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis

BACKGROUND: Monoclonal Antibodies directed at the spike protein of SARS-COV-2 are approved by the FDA for Emergency Use for outpatients with COVID- 19 who are at risk for severe complications. Here we present a single center experience using Bamlanivimab and Casirivimab/Imdevimab to prevent hospital...

Descripción completa

Detalles Bibliográficos
Autores principales: Chundi, Vahini, Wenner, Jennifer J, Scheib, Christopher, Patel, Yatin, snider, Cynthia, Hatcher, Jeffrey C, McQuaid, Douglas B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644489/
http://dx.doi.org/10.1093/ofid/ofab466.705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644489/
http://dx.doi.org/10.1093/ofid/ofab466.705

Ejemplares similares